Tag: Development of Vaccines

Development of vaccines can be simplified into two broad stages:
1. Pre-clinical development is research carried out in lab assays and on animals. It includes:
– Identification (discovery) of relevant antigens (e.g. screening)
– Creation of the vaccine concept
– Evaluation of vaccine efficacy in test tubes and animals
– Manufacture of the vaccine to Good Manufacturing Practice standards
2. Clinical development is when the vaccine is first tested in humans. It covers four stages over several years, from initial clinical trials in humans (phase I) right through to introduction and beyond (phase IV). Clinical development is built on rigorous ethical principles of informed consent from volunteers, with an emphasis on vaccine safety as well as efficacy.

Seqirus joined the Universal Influenza Vaccine Initiative

influenza vaccine
The Human Vaccines Project, a nonprofit public-private partnership, and Seqirus, a global leader in the prevention of influenza, announced that Seqirus is joining the Project's Universal Influenza Vaccine Initiative.

Russia completed development of a highly effective combined vaccine

Microgen completed development of combined vaccine against measles, rubella and mumps. Vactrivir will be the first Russian combined drug providing protection against three dangerous diseases.

OBL Pharm meets GMP requirements of the Russian Federation

In early June 2018, the Russian Ministry of Industry and Trade issued to OBL Pharm the Conclusion GMP-0144-000263/18 on compliance with the requirements of the good manufacturing practice (GMP of the Russian Federation).

Russia is developing a recombinant cholera vaccine

Scientists from the State Research Institute of Highly Pure Biopreparations of the FMBA of Russia are developing a cholera vaccine. Unlike traditional vaccines, it will be created without using any living bacteria fragments.

Targovax secures a patent from the European Patent Office

Targovax, is a Norwegian clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, announced that the European Patent Office had granted European Patent.

Australian scientists advanced in the development of effective malaria vaccine

Australian researchers have identified a novel process used by the immune system to kill and clear malaria, a discovery that could facilitate the development of effective malaria vaccines.

Cancer Research UK and Asterias started a trial of immunotherapy vaccine

A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics.

Sanofi Pasteur and Translate Bio will cooperate on mRNA vaccines

Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur, to develop mRNA vaccines.

Microgen developed live influenza vaccine for children in the form of spray

The new product of NPO Microgen, a subsidiary of Nacimbio pharmaceutical holding company (a part of Rostec Corporation), is the first Russian live influenza vaccine in liquid form that does not require intramuscular injections.

Vaccine and cancer drugs production facility can be setup in the Vector Center

Two unfinished construction projects located at the production site of Vector State Research Center of Virology and Biotechnology may be used to establish production and warehouse facility.

Swiss cancer vaccine startup Nouscom named its new Chief Medical Officer

Nouscom, an immuno-oncology company developing neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced the appointment of Adrian Woolfson M.D., Ph.D. as CMO.

GeoVax Labs earned a research grant for novel Zika vaccine development

vaccine manufacturing
GeoVax Labs, a biotechnology company, announced that the National Institute of Allergy and Infectious Diseases has awarded the Company a Small Business Innovative Research grant in support of its Zika vaccine development program.

GC Pharma launched new company focused on novel vaccine development

GC Pharma, a South Korean biopharmaceutical company, announced the establishment of Curevo Inc. The newly established Seattle-based company's goal is to support GC Pharma's vaccine development activities.

FluGen starts a clinical study of its novel influenza vaccine

FluGen announced that the first subject has been dosed in a clinical study in Belgium which will challenge subjects with an influenza virus genetically mismatched by six years from the influenza strain utilized in the vaccine.

A new vaccine against group B streptococcus was developed in St. Petersburg

Researchers at the Institute of Experimental Medicine (St. Petersburg) have developed a new vaccine against group B streptococcus (Streptococcus agalactiae).

Provention Bio and Intravacc became partners to develop Coxsackievirus B vaccine

Provention Bio, a clinical stage biopharmaceutical company, selected Netherlands-based Intravacc to lead product development and manufacturing of clinical trial material for Provention’s Coxsackievirus B (CVB) vaccine.